Therapeutic peptides for cancer therapy. Part I - peptide inhibitors of signal transduction cascades

被引：65

作者：

Bidwell, Gene L., III ^{[1
]}

Raucher, Drazen ^{[1
]}

机构：

[1] Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA

来源：

EXPERT OPINION ON DRUG DELIVERY | 2009年 / 6卷 / 10期

关键词：

c-Myc; drug delivery; Jun-N-terminal kinase; NF-kappa B; p53; Ras; therapeutic peptide; NF-KAPPA-B; C-TERMINAL PEPTIDE; MOLECULAR-DYNAMICS CALCULATIONS; INDUCED OOCYTE MATURATION; ELASTIN-LIKE POLYPEPTIDE; BINDING DOMAIN PEPTIDE; ACTIVATING PROTEIN GAP; WILD-TYPE RAS-P21; NUCLEAR-LOCALIZATION SEQUENCE; NUCLEOTIDE EXCHANGE PROTEIN;

D O I：

10.1517/17425240903143745

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Therapeutic peptides have great potential as anticancer agents owing to their ease of rational design and target specificity. However, their utility in vivo is limited by low stability and poor tumor penetration. Objective: The authors review the development of peptide inhibitors with potential for cancer therapy. Peptides that inhibit signal transduction cascades are discussed. Methods: The authors searched Medline for articles concerning the development of therapeutic peptides and their delivery. Results/conclusion: Given our current knowledge of protein sequences, structures and interaction interfaces, therapeutic peptides that inhibit interactions of interest are easily designed. These peptides are advantageous because they are highly specific for the interaction of interest, and they are much more easily developed than small molecule inhibitors of the same interactions. The main hurdle to application of peptides for cancer therapy is their poor pharmacokinetic and biodistribution parameters. Therefore, successful development of peptide delivery vectors could potentially make possible the use of this new and very promising class of anticancer agents.

引用

页码：1033 / 1047

页数：15

共 120 条

[11] RAS GENES [J].

BARBACID, M .

ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :779-827

[12]

Barbacid M, 1986, Princess Takamatsu Symp, V17, P43

[13] In vitro inhibition of Ras-Raf association by short peptides [J].

Barnard, D ;

Sun, HY ;

Baker, L ;

Marshall, MS .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 247 (01) :176-180

[14] Identification of the critical features of a small peptide inhibitor of JNK activity [J].

Barr, RK ;

Kendrick, TS ;

Bogoyevitch, MA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (13) :10987-10997

[15] Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides [J].

Bidwell, Gene L., III ;

Davis, Aisha N. ;

Raucher, Drazen .

JOURNAL OF CONTROLLED RELEASE, 2009, 135 (01) :2-10

[16] Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc [J].

Bidwell, GL ;

Raucher, D .

BIOCHEMICAL PHARMACOLOGY, 2006, 71 (03) :248-256

[17] Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy [J].

Bidwell, GL ;

Raucher, D .

MOLECULAR CANCER THERAPEUTICS, 2005, 4 (07) :1076-1085

[18] NF-KB activation in human breast cancer specimens and its role in cell proliferation and apoptosis [J].

Biswas, DK ;

Shi, Q ;

Baily, S ;

Strickland, I ;

Ghosh, S ;

Pardee, AB ;

Iglehart, JD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (27) :10137-10142

[19] MYC AND MAX ASSOCIATE INVIVO [J].

BLACKWOOD, EM ;

LUSCHER, B ;

EISENMAN, RN .

GENES & DEVELOPMENT, 1992, 6 (01) :71-80

[20] Peptide inhibitors of protein kinases - discovery, characterisation and use [J].

Bogoyevitch, MA ;

Barr, RK ;

Ketterman, AJ .

BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2005, 1754 (1-2) :79-99

← 1 2 3 4 5 6 7 8 9 10 →